Marie Zhu
Chief Technology Officer WuXi XDC
Seminars
Tuesday 4th November 2025
Expediting Development of Novel ADCs Through WuXi XDC’s Innovative Technology Platform & Fully Integrated CMC Services
6:15 pm
- Exploring WuXiDAR4, WuXi XDC’s proprietary conjugation technology which produces more homogenous ADC compared to the DAR4 ADC generated through random conjugation. This results in enhanced efficacy, improved (PK), and a superior safety profile in clinical trials
- Sharing WuXi XDC’s novel linker and payload-linker, which enables the development of better ADCs with increased stability and a wider therapeutic index
- Showcasing our one-stop discovery service platform, which accelerates the selection of pre-clinical candidates, and our fully integrated CMC service, which reduce the ADC development timeline from DNA to IND filing to just 13-15 months
